Kenneth Beckman, MD
Ophthalmology · Westerville, OHNPI 1699731018
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $244,464 of the $400,182 with a category attached, or 61.1%. 38 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 26.9% of the total. 2025 is the largest year on record at $109,472, 2.0 times the $53,404 reported in 2019. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $632.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$108K
- Glaukos Corporation$55K
- Alcon$37K
- Dompe US, Inc.$36K
- AbbVie$24K
- Amgen$21K
- plus $119K from 32 others
Across 109 payments — averaging $4052.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$252K
- Avedro Inc.$181K
- Aerie Pharmaceuticals, Inc.$9K
- Alcon Research LLC$537
What the payments were for
- Consulting fees$244,46461%
- Speaking & faculty fees$100,70525%
- Travel & lodging$18,0085%
- Food & beverage$21,6735%
- Education$180%
- Gifts$390%
- Other$15,2754%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$70,264
- XIIDRA$62,168
- Oxervate$26,657
- TRYPTYR$20,786
- TEPEZZA$17,289
- Epioxa$15,750
- CEQUA$14,157
- LOTEMAX SM$10,519
- ENVISTA ENVY IOL$10,285
- Crystalens Accommodating IOL (AT-52AO)$10,173
- EYSUVIS$7,792
- TYRVAYA$7,629
- CE-marked KXLA system$6,506
- Flarex$6,347
- KXL System$6,075
- VUITY$4,982
- Systane$4,655
- DURYSTA$4,275
- enVista MX60 IOL$4,090
- ARTEVO 800$3,200
How this compares
$400,182 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 244 | $284,658 |
| XiidraLifitegrast | 92 | $97,116 |
| TyrvayaVarenicline Tartrate | 86 | $66,049 |
| MieboPerfluorohexyloctane/Pf | 66 | $50,765 |
| Cyclosporine | 69 | $42,063 |
| CequaCyclosporine | 15 | $13,319 |
| LumiganBimatoprost | 33 | $13,231 |
| Prednisolone Acetate | 264 | $9,041 |
| EysuvisLoteprednol Etabonate | 18 | $8,595 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $5,520 |
| Brimonidine Tartrate | 127 | $5,439 |
| FlarexFluorometholone Acetate | 36 | $5,171 |
| ValacyclovirValacyclovir Hcl | 102 | $4,029 |
| Loteprednol Etabonate | 28 | $3,272 |
| Latanoprost | 430 | $3,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $24,393 | $300,837292 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $107,592 | $147,882158 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $9,885 | $66,04986 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $14,853 | $13,31915 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $8,165 | $8,59518 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $30 | $5,52013 claims |
| Eyevance Pharmaceuticals LLCFlarex | $7,669 | $5,17136 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $14,422 | $3,27228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Westerville
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.